TABLE 1:
Brain MR imaging results in 10 patients with MS
| Patient/Age, y/Sex | No. of Enhancing Lesions |
Total Enhancing Area, cm2 |
Mean Lesion CNR |
||||||
|---|---|---|---|---|---|---|---|---|---|
| SD | DD | TD | SD | DD | TD | SD | DD | TD | |
| 1/35/M | 0 | 1 | 3 | 0 | 0.3 | 0.7 | 0 | 0.5 | 4.9 |
| 2/42/F | 0 | 0 | 1 | 0 | 0 | 0.2 | 0 | 0 | 16.0 |
| 3/38/F | 3 | 6 | 7 | 2.0 | 2.6 | 3.0 | 17.8 | 24.7 | 48.4 |
| 4/52/F | 1 | 1 | 3 | 0.5 | 0.5 | 0.7 | 4.1 | 7.6 | 15.0 |
| 5/46/M | 1 | 1 | 2 | 0.3 | 0.3 | 0.6 | 10.1 | 19.1 | 13.7 |
| 6/34/F | 0 | 1 | 2 | 0 | 0.7 | 0.9 | 0 | 3.1 | 5.0 |
| 7/42/M | 0 | 0 | 1 | 0 | 0 | 0.5 | 0 | 0 | 15.2 |
| 8/34/F | 0 | 2 | 2 | 0 | 0.4 | 0.5 | 0 | 10.8 | 26.9 |
| 9/41/M | 1 | 1 | 1 | 0.4 | 0.5 | 0.5 | 13.4 | 10.2 | 12.9 |
| 10/26/F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total or mean | 6 | 13 | 22 | 3.2 | 5.3 | 7.6 | 13.5 | 16.2 | 24.3 |
| Mean per patient | 0.6 | 1.3 | 2.2 | 0.3 | 0.5 | 0.8 | NA | NA | NA |
Note—CNR indicates the contrast-to-noise ratio; NA, not applicable; SD, single dose (0.1 mmol/kg) of gadodiamide; DD, double dose (0.2 mmol/kg) of gadodiamide; and TD, triple dose (0.3 mmol/kg) of gadodiamide.